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Acute loss of TET function results in aggressive
myeloid cancer in mice
Jungeun An1,w, Edahı´ Gonza´lez-Avalos1, Ashu Chawla1, Mira Jeong2, Isaac F. Lo´pez-Moyado1, Wei Li3,
Margaret A. Goodell2,3, Lukas Chavez1,4, Myunggon Ko1,5 & Anjana Rao1,6,7
TET-family dioxygenases oxidize 5-methylcytosine (5mC) in DNA, and exert tumour
suppressor activity in many types of cancers. Even in the absence of TET coding region
mutations, TET loss-of-function is strongly associated with cancer. Here we show that acute
elimination of TET function induces the rapid development of an aggressive, fully-penetrant
and cell-autonomous myeloid leukaemia in mice, pointing to a causative role for TET loss-of-
function in this myeloid malignancy. Phenotypic and transcriptional proﬁling shows aberrant
differentiation of haematopoietic stem/progenitor cells, impaired erythroid and lymphoid
differentiation and strong skewing to the myeloid lineage, with only a mild relation to changes
in DNA modiﬁcation. We also observe progressive accumulation of phospho-H2AX and
strong impairment of DNA damage repair pathways, suggesting a key role for TETproteins in
maintaining genome integrity.
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E
nzymes of the TET (ten-eleven translocation) family are
dioxygenases that convert 5-methylcytosine (5mC) to
5-hydroxymethylcytosine (5hmC) and the further oxida-
tion products 5-formylcytosine (5fC) and 5-carboxylcytosine
(5caC)1–4. Together these oxidized methylcytosines (oxi-mC)
facilitate DNA demethylation and also function as epige-
netic marks5–7. Loss-of-function mutations in TET2 are
associated with diverse myeloid and lymphoid malignancies in
humans8–10, but diminished TET expression or activity are also
prominent features of numerous other cancers including
melanoma and glioblastoma; moreover, low TET1 levels in
breast and other cancers have been shown to correlate with
advanced disease, metastases and poor patient survival
(reviewed in refs 11,12). Nevertheless, the molecular connec-
tions between TET loss-of-function and oncogenic
transformation remain to be deﬁned.
In humans, TET2 is recurrently deleted or mutated in a wide
range of myeloid malignancies including myelodysplastic
syndromes, myeloproliferative neoplasms, chronic myelomono-
cytic leukaemia, acute myeloid leukaemia and secondary
acute myeloid leukaemia, as well as in T-cell lymphomas
including angioimmunoblastic T-cell lymphoma and peripheral
T-cell lymphoma-not otherwise speciﬁed8–10,13,14. The TET2
mutations observed in these conditions are inactivating loss-of-
function mutations that impair 5mC oxidation and are associated
with decreased genomic 5hmC levels2; however, the development
of full-blown malignancy requires a second hit11,12.
To model this phenomenon, we and others have generated and
studied Tet-deﬁcient mice8,15–18. Tet2 and Tet3 are both highly
expressed in murine haematopoietic stem/progenitor cells
(HSPCs)2, and their individual deletion in mice results in
aberrant haematopoiesis, characterized by expansion of HSPCs
with enhanced self-renewal capacity, augmented haematopoietic
repopulation and preferential differentiation towards myeloid
lineages8,12,15–17. Certain strains of Tet2-deﬁcient mice develop a
chronic myelomonocytic leukaemia-like disease, but with long
latency and low penetrance8,15,16. Similarly, germline Tet1
deﬁciency in mice is associated with lymphocytosis and the late
development of a poorly penetrant B-cell lymphoma18. Together
these results indicate that loss of a single TET protein is not
sufﬁcient to promote malignancy efﬁciently.
In this study, to explore the relation between TET loss-of-
function and cancer, we generated mice homozygous for a
germline deletion of Tet2 and a conditional allele of Tet3. Our
goal was not to model a human disease, since TET3-coding region
mutations are relatively rare in humans19. Rather, we wished to
examine the relation of TET loss-of-function to oncogenesis,
using a mouse model in which a profound loss of TET function
could be acutely induced in vivo. We show here that Tet2 /
mice acutely deleted for Tet3 displayed a rapid, progressive
leukocytosis with neutrophilia, monocytosis, thrombocytopenia
and severe anaemia, which developed within a few weeks into a
highly aggressive myeloid leukaemia in 100% of the mice.
Transcriptional proﬁling revealed aberrant lineage priming20 in
HSPC, coupled to impaired erythroid and lymphoid
differentiation and marked skewing towards the myeloid
lineage. These changes in gene transcription were not strongly
linked to changes in DNA methylation. Bone marrow chimera
and splenocyte transfer experiments indicated that the myeloid
leukaemia was induced in a cell-autonomous manner and was
transplantable to secondary recipient mice. Myeloid progenitors
and mature myeloid-lineage cells acutely deleted for TET
function progressively accumulated DNA damage and showed
strong impairment of DNA damage responses and DNA break
repair. Our data indicate that TET loss-of-function accelerates
myeloid leukaemogenesis, through mechanisms that involve
lineage dysregulation, uncontrolled expansion and genomic
instability in differentiating cells.
Results
Acute loss of TET function results in myeloid leukaemia. To
diminish TET function profoundly in adult mice, we ﬁrst set up
an inducible system whereby Tet3 could be acutely deleted in
haematopoietic precursor cells in the context of a germline
deletion of Tet2 (Tet2 / Tet3ﬂ/ﬂ Mx1-Creþ mice)12,17.
The mice were injected ﬁve times with polyinosine–polycytidine
(pIpC) over a 10-day period, a regimen that induces
Cre recombinase expressed under control of the interferon-a-
inducibleMx1 promoter21. After 2 weeks, we observed a complete
loss of Tet3 messenger RNA expression in several haematopoietic
cell types, with no compensatory upregulation of Tet1
(Supplementary Fig. 1a). Loss of TET function was monitored
at 2 and 4 weeks after pIpC injection by anti-cytosine-5-
methylenesulfonate dot blot of bisulﬁte-treated genomic DNA2.
Ablation of either Tet2 or Tet3 led to a modest (approximately
twofold) decrease in 5hmC levels in the bone marrow and spleen,
but deletion of both genes led to an almost complete loss of 5hmC
(Fig. 1a; Supplementary Fig. 1b–e). Thus Tet2 and Tet3 are the
main enzymes that catalyse 5hmC production in cells of the
haematopoietic system.
Between 3 and 7 weeks after pIpC injection, 100% of injected
Tet2/3 DKO mice became very sick and were euthanized,
whereas all wild-type (WT) and singly-deﬁcient mice (Tet2 /
or Tet3ﬂ/ﬂ Mx1-Creþ ) survived (Fig. 1b; Supplementary Table 1).
Examination of peripheral blood showed that DKO mice
developed progressive leukocytosis, mainly due to expansion
of myeloid-lineage cells including neutrophils, monocytes,
eosinophils and basophils, with concomitant development of
profound anaemia and thrombocytopenia (Fig. 1c,d;
Supplementary Fig. 2). Flow cytometry conﬁrmed progressive
ampliﬁcation of myeloid-lineage cells in the peripheral blood of
DKO mice: Gr-1þ Mac-1þ granulocytes increased within 2 days
of the last pIpC injection, with Gr-1 Mac-1þ monocytes
expanding at somewhat later times (Fig. 1e; Supplementary
Fig. 3a–c), and the percentages of B and T lymphoid cells showing
a gradual decrease (Supplementary Fig. 3d,e).
In all Tet2/3 DKO mice, myeloid expansion was accompanied
by massive, progressive splenomegaly and hepatomegaly (Fig. 1f;
Supplementary Fig. 4a). This was at least partly due to
extramedullary haematopoiesis, since DKO spleen and liver cells
displayed an increased ability to form haematopoietic colonies
in vitro (Fig. 1g). We also observed disruption of normal splenic
architecture and pronounced inﬁltration of liver, lung, bone
marrow and spleen with haematopoietic cells in Tet2/3 DKO
mice (Supplementary Figs 4 and 5). In the liver, the inﬁltrating
cells were myeloperoxidase positive (Fig. 1h; Supplementary
Fig. 4d) and were identiﬁed as Gr-1þ /Mac-1þ myeloid-lineage
cells by ﬂow cytometry (Supplementary Fig. 6). Staining of DKO
bone marrow aspirates revealed a preponderance of myeloid cells
of uniform appearance (myeloblasts, granulocytes and
monocytes), whereas WT bone marrow showed the normal
heterogeneous pattern of trilineage maturation (Supple-
mentary Fig. 5e).
As expected from our examination of peripheral blood
(Supplementary Fig. 2), Tet2/3 DKO mice developed
profound anaemia and lymphopenia. Bones isolated from
Tet2/3 DKO mice (but not Tet2 KO or Tet3 KO mice) were
pale and their bone marrow contained reduced numbers of
cells (Fig. 2a,b). At both early (2–2.5 weeks) and late (4–5 weeks)
times after pIpC injection, we observed a substantial increase
in the frequency of Gr-1þ / Mac-1þ myeloid-lineage cells
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in liver, bone marrow and spleen, a marked decrease in the
frequency of Ter-119þ erythroid cells and B220þ B cells in
bone marrow, and a striking decrease in the fraction of B220þ
B cells, CD4þ and CD8þ T cells in liver and spleen of Tet2/3
DKO mice compared with WT (Fig. 2c–e; Supplementary
Figs 6–8).
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Figure 1 | Acute deletion of Tet3 in Tet2-deﬁcient mice results in myeloid leukaemia. (a) Quantiﬁcation of 5hmC levels in Tet2/3 DKO bone marrow 4
weeks after pIpC injection by anti-CMS dot blot. (b) Kaplan–Meier curve representing percent survival of WT (n¼ 23) and DKO (n¼ 14) mice over time
after pIpC injection. No lethality was observed for WT, Tet2-deﬁcient (n¼4) and Tet3-deﬁcient (n¼ 6) mice during this period. Strategy for conditional
deletion of Tet3 in adult mice is shown above. For exact genotypes, see Methods. (c) May–Gru¨nwald–Giemsa-stained peripheral blood smears, 4 weeks
after pIpC administration (n¼ 7). Scale bar, 20mm. (d) Time-course analysis of peripheral blood cell counts after acute deletion of Tet3 in Tet2-deﬁcient
mice (means±s.e.m.). DKO mice developed progressive leukocytosis with neutrophilia (n¼ 7B10 per genotype at each time point examined). *Po0.05,
**Po0.005 (Student’s t-test). Also see Supplementary Fig. 2. (e) Expansion of myeloid-lineage cells in DKO mice. Flow cytometric analysis of myeloid cells
in the peripheral blood of WT (n¼ 7) or DKO (n¼ 7) mice was performed at 4 weeks following pIpC injection. Bottom, summary of results
(means±s.e.m.). For kinetic analyses of myeloid, B- and T-cell lineages over the entire time course, see Supplementary Fig. 3. **Po0.005, ***Po0.0005
(Student’s t-test). (f) Enlargement of spleens in Tet2/3 DKO mice at 2B2.5 weeks following pIpC injection. Top—representative photographs. Bottom—
spleen weights and cellularity (n¼ 7B13 and 4B6 per genotype) at 2–2.5 or 4–5 weeks after pIpC injection (means±s.e.m.). **Po0.005, ***Po0.0005
(Student’s t-test). (g) Extramedullary haematopoiesis in spleen and liver of Tet2/3 DKO mice. Cells were harvested from the spleen (left) or liver (right) of
WTand diseased Tet2/3 DKO mice and 105 nucleated cells were plated in methylcellulose medium. Colony-forming units were assessed by counting cell
colonies 7 days after plating. ***Po0.0005 (Student’s t-test) (h) Myeloperoxidase staining of livers at 4 weeks after pIpC injection (40 magniﬁcation).
For liver weight and histological analysis data, see Supplementary Fig. 4a–d. Scale bar, 60mm.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10071 ARTICLE
NATURE COMMUNICATIONS | 6:10071 | DOI: 10.1038/ncomms10071 | www.nature.com/naturecommunications 3
Taken together, these results indicate that Tet2 and Tet3 play
redundant roles in the haematopoietic system and can
compensate for one another to suppress malignant transforma-
tion. Acute loss of Tet3 in the context of a germline Tet2
deletion results in rapid and progressive expansion of myeloid-
lineage cells with lymphoid and erythroid dysplasia, ultimately
causing a lethal myeloid neoplasia. On the basis of the criteria
described in the Bethesda proposal for classiﬁcation of
nonlymphoid haematopoietic neoplasms in mice22, these
phenotypes are characteristic of myeloproliferative disorders-
like myeloid leukaemia.
Profound loss of TET function affects HSPC. We examined the
impact of TET deﬁciency on haematopoietic stem cell (HSC) and
progenitor compartments in the bone marrow. Loss of Tet2 and
Tet3 led to a striking increase in the percentage of LSK cells
within the lineage-negative (Lin ) population, but because the
frequency of the Lin population was greatly reduced, the
average number of LSK cells in total bone marrow was unchanged
or slightly decreased (Fig. 3a,b; Supplementary Fig. 9a,b).
Notably, DKO LSK and granulocyte–monocyte progenitor
(GMP) cells, but not the corresponding WT, Tet2 KO or Tet3 KO
cells, showed increased serial replating capability when cultured
in methylcellulose in vitro (Fig. 3c; Supplementary Fig. 9f; for the
ﬂowchart of experiment and extent of Tet3 deletion see
Supplementary Fig. 9c–e). In previous studies, Tet2-deﬁcient LSK
cells displayed increased serial replating capacity compared with
WT LSK cells15, but our data show that double-Tet2/Tet3
deﬁciency has an even stronger effect.
Our attempts to determine the impact of Tet2/Tet3 deletion on
HSCs were complicated by the fact that TET loss-of-function
altered HSC marker expression (Supplementary Fig. 10a–c). The
frequency and number of SLAM-marked long-term HSCs
(LT-HSCs, deﬁned as LSK CD150þ CD48 )23 were markedly
decreased in DKO bone marrow (Fig. 3d; Supplementary
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Figure 2 | Combined loss of Tet2 and Tet3 results in expansion of myeloid cells with impaired lymphoid and erythroid differentiation.
(a) Representative photographs of femurs and tibiae at 4 weeks following pIpC injection. Tet2 KO, Tet2 / Tet3ﬂ/ﬂ Mx1-Cre or Tet2 / Mx1-Creþ ;
Tet3 KO, Tet3ﬂ/ﬂ Mx1-Creþ . (b) Total cellularity of bone marrow was assessed at the indicated time points after pIpC injection (n¼ 8B11 per genotype at
each time point). Means±s.e.m. are shown. **Po0.005 (Student’s t-test). (c) Schematic representation of myeloid expansion and impaired lymphoid and
erythroid development upon loss of Tet2 and Tet3. (d,e) Haematopoietic cell development upon simultaneous deletion of Tet2 and Tet3. Flow cytometry was
performed to assess myeloid (Gr-1/Mac-1), erythroid (CD71/Ter-119) and lymphoid (B220/CD4/CD8) cell populations in the bone marrow (d, n¼ 8 per
each genotype) and spleen (e, n¼ 6 per each genotype) of WT or DKO mice. Representative ﬂow cytometry plots (left) and summary graphs (right) at
2B2.5 weeks after pIpC injection are shown. For results at 4B5 weeks, see Supplementary Figs 7 and 8. Means±s.e.m. are shown. **Po0.005,
***Po0.0005 (Student’s t-test).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10071
4 NATURE COMMUNICATIONS | 6:10071 | DOI: 10.1038/ncomms10071 | www.nature.com/naturecommunications
Fig. 10a), but the percentage and numbers of LT-HSCs deﬁned
using different markers (LSK CD34 Flt3 )24 showed a
signiﬁcant increase (Supplementary Fig. 10b,c). Using Flt3 and
CD34 as markers, we documented a decrease in lymphoid-
primed multipotent progenitor cells (LMPP, LSK CD34þ
Flt3hi)25 (Supplementary Fig. 10b,c), and also showed
that within the Flt3lo/ LSK population, the ratio of CD34
(LT-HSC) to CD34þ (ST-HSC) cells was only slightly decreased
in DKO mice (Supplementary Fig. 10d).
To resolve the discrepancy between the two methods of
identifying LT-HSC, we used Hoechst 33342 staining to deﬁne a
‘side population’ that has been shown to be highly enriched for
HSC26. Compared with WT mice, Tet2/3 DKO mice showed a
substantial decrease in the side population of HSCs
(Supplementary Fig. 10e). Moreover, CD150hi CD48 cells
within the LT-HSC population (CD34 Flt3 LSK) in the bone
marrow, which are enriched for a dormant HSC population in
mice27, were decreased in DKO compared with WT bone marrow
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injection (n¼ 6B8). Gating strategy and absolute cell numbers are shown in Supplementary Fig. 11c,d. Means±s.e.m. are shown. *Po0.05, ***Po0.0005
(Student’s t-test). (h) Schematic representation of altered haematopoietic development in Tet2/3 DKO mice.
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(Supplementary Fig. 10f). Together these data suggest that Tet2
and Tet3 act to maintain the size of the HSC pool, but that the
developmental transition from LT- to ST-HSCs is largely
unaffected in the absence of Tet2 and Tet3. CD48 is among the
ﬁrst markers to be upregulated when HSCs transition out of the
stem cell compartment28, hence the striking acquisition of CD48
on cells that otherwise resemble LT-HSCs suggests that
HSC function is skewed towards myeloid progenitor cells in
Tet2/3 DKO mice, consistent with the transcriptional proﬁles
described below.
The developmental bias observed in Tet2/3 DKO mice
correlated strongly with alterations in the distribution of early
lymphoid and myeloid progenitors in bone marrow (Fig. 3a). The
percentages and absolute numbers of megakaryocyte-erythroid
progenitors were substantially reduced in DKO bone marrow
compared with WT; the mice displayed a substantial decrease in
the numbers of common lymphoid progenitors (Lin Flt3þ
CD27þ IL-7Raþ )29, and the size of the common myeloid
progenitor compartment gradually decreased after pIpC injection,
whereas the numbers of GMPs remained unchanged (Fig. 3a,e–g;
Supplementary Fig. 11). In some mice, myeloid progenitor (LK)
populations contained only GMPs (data not shown). These
ﬁndings are consistent with the impaired erythropoiesis,
decreased frequency and number of LMPP, impaired B and
T lymphopoiesis and dominant myelopoiesis observed in Tet2/3
DKO mice (Fig. 3h).
Cell-autonomous leukaemia development in Tet2/3 DKO mice.
Bone marrow chimera and competitive engraftment experi-
ments showed that myeloid leukaemia developed in a
cell-autonomous manner in Tet2/3 DKO mice. CD45.2þ bone
marrow cells from WT or Tet2 / Tet3ﬂ/ﬂ Mx1-Creþ mice
were combined with CD45.1þ competitor cells, followed by
transplantation into lethally irradiated mice. Acute deletion
of Tet3 was induced by pIpC administration 4 weeks after
transplantation (Supplementary Fig. 12a). The proportion of
CD45.2þ donor-derived cells progressively increased for DKO
donors but not for WT donors (Fig. 4a), indicating that Tet2/3
DKO cells possessed a competitive advantage over WT control
cells. Notably, recipients of WT bone marrow cells showed the
normal heterogeneous proﬁle of haematopoietic lineages,
whereas the peripheral blood of chimeric mice that received
Tet2/3 DKO bone marrow cells was dominated by myeloid-
lineage cells (Fig. 4b). None of the mice transplanted with DKO
bone marrow survived longer than 70 days after transplantation
(Fig. 4c). Moreover, the myeloid malignancy induced in Tet2/3
DKO mice was transplantable to sublethally irradiated WT mice
by transfer of splenocytes from pIpC-injected WT or Tet2 /
Tet3ﬂ/ﬂ Mx1-Creþ mice. None of the recipient mice that
received WT splenocytes developed disease. However, transfer
of DKO splenocytes resulted in lethality with 100% penetrance
B1 month after transplantation (Fig. 4d), and the disease course
recapitulated that observed in the primary Tet2/3 DKO donor
mice (Fig. 4e–h, Supplementary Table 2a). Flow cytometry and
histological analysis conﬁrmed a marked expansion of myeloid
cells and erythroblasts and inﬁltration of liver by myeloid cells
(Fig. 4i–k; Supplementary Fig. 12b). Identical results were
obtained when we performed the transfer experiment using
splenocytes from pIpC-injected Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ Mx1-Creþ mice;
bone marrow cells from tamoxifen-treated Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ
Cre-ERT2þ mice; or puriﬁed primary Mac-1þ cells from the
bone marrow of pIpC-injected Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ Mx1-Creþ mice,
a population that includes fully differentiated myeloid cells as
well as Mac-1þ myeloid progenitors and cycling HSC
(Supplementary Figs 13–15; Supplementary Tables 2b–d).
Together these data show that acute deletion of Tet3 in a
Tet2-deﬁcient context, or concurrent deletion of both Tet2 and
Tet3, leads to the rapid cell-autonomous induction of an
aggressive, transplantable myeloid leukaemia in mice. Limiting
dilution experiments with puriﬁed stem cells will be needed to
determine whether Tet2/3 DKO cells cause leukaemia by
acquiring a true stem cell advantage such as increased
self-renewal.
Aberrant lineage priming in Tet2/3 DKO HSPC. To delineate
the mechanism by which Tet2 and Tet3 inﬂuence early
haematopoiesis, we performed RNA sequencing on duplicate
samples of WT and Tet2/3 DKO LSK cells (Supplementary
Tables 3 and 4). About twice as many genes were upregulated
(n¼ 1,406) as downregulated (n¼ 732) in Tet2/3 DKO compared
with WT LSK cells (Fig. 5a; Supplementary Data 1). Genes
upregulated in Tet2/3 DKO compared with WT LSK cells were
strongly enriched for myeloid30,31 (Fig. 5b) and pre-granulocyte/
macrophage progenitor (pre-GM)32 gene signatures, whereas
genes with HSC33, pre-megakaryocyte/erythrocyte progenitors32
and common lymphoid progenitors32 signatures were down-
regulated (Supplementary Fig. 16a). Figure 5c shows genome
browser views of the RNA-seq data for selected myeloid
(Mpo, Csf1r) or lymphoid (Dntt, Cd72) genes that were
upregulated or downregulated, respectively, in Tet2/3 DKO
compared with control LSK cells.
Genes implicated in lymphoid, myeloid and erythroid-lineage
commitment are co-expressed in HSCs, a process known as
lineage priming20, and their expression is differentially up- or
downregulated as appropriate during subsequent lineage
restriction and differentiation. Compared with WT LSK cells,
Tet2/3 DKO LSK cells showed downregulation of numerous
genes whose expression is enriched in HSC31,34,35, including
‘stem’ genes31 and genes reported to induce reprogramming of
committed haematopoietic cells towards induced HSCs34. They
also showed downregulation of s-mpp genes31 expressed in
multipotent progenitors (MPP) and LMPPs; erythroid genes
that are primed in HSC (s-ery)31; and lymphoid genes such as
Dntt, Satb1, Notch1, Sox2, Cd72 and Ets1 (Supplementary
Fig. 16b–d). In contrast, they tended to upregulate myeloid-
lineage genes that were primed in HSC (s-myly)31, and displayed
premature induction of many myeloid genes normally expressed
in GMP (d-my)31 (Supplementary Fig. 16d).
Taken together, these results indicate that Tet2 and Tet3
normally induce stem cell-related genes, promote lymphoid and
erythroid priming, and prevent the premature induction of late
myeloid genes in early haematopoietic progenitors, thus support-
ing the undifferentiated state of HSCs; consequently, their loss
leads to myeloid skewing. These molecular ﬁndings are well
aligned with the observed developmental phenotype of the Tet2/3
DKO bone marrow, in which production of LMPPs and
megakaryocyte-erythroid progenitors is impaired, but production
of myeloid progenitors (particularly GMPs) remains intact.
Lack of relation between transcription and DNA methylation.
To relate changes in gene expression to changes in DNA
modiﬁcation, we performed whole-genome bisulﬁte sequencing
on WT and Tet2/3 DKO LSK cells (Supplementary Table 5; see
Methods). Because bisulﬁte sequencing does not distinguish
between 5mC and 5hmC36, we use the term DNA modiﬁcation in
preference to DNA methylation; however, because of the very low
level of 5hmC in Tet2/3-deﬁcient bone marrow cells (Fig. 1a),
most of the observed signal of unconverted C is likely due to 5mC
with little or no contribution from 5hmC.
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Overlaid upon the typical bimodal distribution of DNA
methylation in both WT and Tet2/3 DKO LSK cells, we observed
a slight but consistent increase of 5mCþ 5hmC throughout the
transcription start site (TSS)/promoter and gene body regions in
Tet2/3 DKO compared with WT LSK cells (Supplementary
Fig. 17a–c). This increase was reproducible (compare the
triplicate biological samples from WT and DKO cells;
Supplementary Fig. 17c, left panel); speciﬁc (it was not seen in
randomly chosen genome fragments of similar size;
Supplementary Fig. 17c, right panel); and limited in extent
(Supplementary Fig. 17a,b), most likely reﬂecting the fact that
5hmC is only a minor proportion of 5mC (5–10%). The results
support the well-established notion that TET proteins regulate
DNA cytosine modiﬁcation and facilitate DNA demethy-
lation1,5,7,37,38. A similar small average increase was observed in
differentially expressed genes, regardless of whether they were
upregulated or downregulated in Tet2/3 DKO compared with WT
cells (Fig. 5d).
To examine changes in DNA modiﬁcation at the level of
individual TSS regions and gene bodies, we divided the distance
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Figure 4 | Cell-autonomous development of transplantable myeloid leukaemia in Tet2/3 DKO mice. (a) Competitive repopulation assay using bone
marrow cells from inducible chimeric mice. Red blood cell-depleted CD45.2þ bone marrow cells from Tet2þ /þ Tet3ﬂ/ﬂ Mx1-Cre (WT) or Tet2 /
Tet3ﬂ/ﬂ Mx1-Creþ (DKO) mice were mixed with equal numbers of CD45.1þ competitor cells and transplanted into lethally irradiated CD45.1þ congenic
B6.SJL mice (see Supplementary Fig. 12a). At 4 weeks after transplantation, Tet3 deletion was induced by administration of pIpC and peripheral blood was
examined for donor chimerism at the indicated time points after pIpC injection. (b) Analysis of multilineage differentiation as percentage of peripheral
blood cells within donor-derived (CD45.2þ ) cells. Myeloid cells (Mac-1þ ), B cells (B220þ ), T cells (CD3eþ ). (c) Kaplan–Meier curve representing
percent survival of bone marrow chimeric mice that received WTor Tet2/3 DKO cells after pIpC injection (n¼ 8 per group). No lethality was observed for
recipients of WT bone marrow cells. (d) Kaplan–Meier curve representing percent survival of recipient mice transplanted with 2 106 splenocytes from
WTand diseased Tet2/3 DKO mice (n¼9 per group). (e) May–Gru¨nwald–Giemsa-stained peripheral blood smears of recipient mice. Scale bar, 20mm. (f,g)
Enlargement of spleens and livers of recipient mice. Representative photographs of spleen (f) and liver (g) from recipients of control or Tet2/3 DKO
splenocytes. Weights of spleen or liver are shown below (n¼ 7 per group). Means±s.e.m. are shown. ***Po0.0005 (Student’s t-test). (h) Representative
photographs of femurs and tibiae from recipients of WTor Tet2/3 DKO splenocytes. (i) A representative ﬂow cytometric analysis of myeloid-lineage cells
(Gr-1þ/Mac-1þ ) in bone marrow, spleen and blood of recipient mice (n¼ 5 per each group). (j) A representative ﬂow cytometric analysis of erythroid-
lineage cells (Ter-119þ/CD71þ ) in bone marrow and spleen of recipient mice (n¼ 5 per each group). (k) Haematoxylin and eosin staining and
immunohistochemistry (IHC) of livers with anti-myeloperoxidase show loss of normal liver structure and inﬁltration with myeloid cells. Top, 4
magniﬁcation; middle and bottom, 40 magniﬁcation. Scale bar, 200mm (upper panel) and 60mm (middle panel).
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from the TSS to the transcription termination site for each
differentially expressed gene into 100 bins, calculated the average
change in DNA modiﬁcation within each gene body (bins
26–100) and at each promoter (±2 kb relative to the TSS) and
plotted the values against the log2-fold change in expression of
the corresponding gene (Fig. 5e). The resulting dot plot conﬁrms
that the slight to moderate increase in average DNA modiﬁcation
at gene bodies and promoters in Tet2/3 DKO compared with WT
LSK cells occurs independently of the direction of change in
gene transcription, since it is similar for upregulated versus
downregulated genes.
Since these ﬁndings run counter to previous reports of a strong
inverse correlation between promoter methylation and gene
expression39, we also examined differentially modiﬁed regions,
CpG islands (CGIs)40, CGI shores41 and the subset of long
(Z3.5 kb) undermethylated regions classiﬁed as ‘canyons’42. The
majority of differentially modiﬁed regions (3,864/5,555; B70%)
gained methylation in Tet2/3 DKO LSK cells compared with WT;
they were depleted from intergenic regions and enriched in
promoter/TSS regions and gene bodies (Supplementary Fig. 17d;
Supplementary Table 6). As previously described41, DNA
methylation increased primarily at CGI shores rather than
within CGIs in Tet2/3 DKO compared with WT cells, but only
a minority of CGI shores within or at promoter regions (±2 kb)
showed increased DNA modiﬁcation (1,539/12,005 (12.8%);
Supplementary Fig. 18a, left). Moreover, for CGI shores within
or at promoter regions (±2 kb), there was no clear correlation
between the observed change in DNA modiﬁcation and the
change in expression level of the associated genes (Supplementary
Fig. 18a, right; Supplementary Data 2).
Among the undermethylated regions in WT LSK cells, we
deﬁned 1,135 canyons42 (see Methods); of these, 846 were located
in close proximity (o2 kb) to 841 gene promoters (Supple-
mentary Fig. 18b, top). Only 105 of these genes (12.4%) showed
signiﬁcantly altered expression, but more were downregulated
(n¼ 77) than upregulated (n¼ 28) in Tet2/3 DKO compared with
WT LSK cells (Supplementary Fig. 18b, top). As expected, more
canyons (465; 41%) gained DNA methylation at canyon edges in
Tet2/3 DKO LSK cells relative to WT, compared with 59 (5.25%)
that lost DNA methylation (Supplementary Fig. 18b, middle and
bottom; Supplementary Fig. 18c); but again, only a minority of
genes associated with shrinking and expanding canyons showed
altered expression by RNA-seq (93/524; 17.7%). Of the 86
differentially expressed genes associated with shrinking canyons,
67 were downregulated and 19 were upregulated (Supplementary
Fig. 18d, left; Supplementary Data 3); this difference was
statistically signiﬁcant (P valueo2.834 e 96, w2-test).
Finally, Tet2/3 DKO LSK cells showed moderate hypermethy-
lation compared with WT LSK cells at active enhancers
previously deﬁned in LT-HSC43 (Fig. 5f,g); note the decrease in
modiﬁcation from WT to DKO in the area of low modiﬁcation at
the enhancer centre, and the increase in density of CpGs with a
high modiﬁcation level across the entire enhancer region in the
red area of near 100% modiﬁcation from DKO to WT (Fig. 5f).
Thus some active enhancers have low levels of DNA modiﬁcation
(5mCþ 5hmC) and TET proteins maintain this unmodiﬁed state;
however, some active enhancers contain high levels of DNA
modiﬁcation, potentially 5hmC44, but these regions are also
subject to increased modiﬁcation (most likely hypermethylation)
upon loss of TET proteins. We have not attempted to correlate
changes in DNA modiﬁcation at enhancers to gene expression,
since it is not yet straightforward to identify the gene(s)
controlled by a given enhancer43,45.
Overall, TET loss-of-function is primarily associated with
canyon shrinking and enhancer hypermethylation, and canyon
shrinking is more strongly associated with downregulation than
upregulation of gene expression. The results are consistent with
previous ﬁndings that increased DNA methylation at canyon
edges often results in decreased gene expression42, and conﬁrm,
for some genes, that increased promoter methylation correlates
with decreased gene expression39. However, the identities of the
up- and downregulated genes did not generally shed light on
myeloid skewing or downregulation of HSC-expressed, erythroid
and lymphoid genes in Tet2/3 DKO compared with WT LSK
cells. For instance, Car2 (encoding carbonic anhydrase 2) and
Gcnt2 (encoding glucosaminyl (N-acetyl) transferase 2, the
I-branching enzyme that generates the I blood group antigen)
were among the most downregulated genes associated with
shrinking canyons in Tet2/3 DKO LSK cells compared with WT
(Supplementary Fig. 18d,e); to the best of our knowledge,
however, the functions of these genes have not been associated
speciﬁcally with haematopoietic differentiation or oncogenesis.
Tet2/3 DKO cells show DNA damage and impaired DNA repair.
Genome instability, arising from replication stress or DNA
lesions coupled with defective DNA damage checkpoints and
repair, promotes the accumulation of mutations and
chromosomal aberrations that drive progression to malignancy46.
Beginning at 2 weeks after pIpC injection, there was strong
spontaneous accumulation of phosphorylated histone H2A.X
(gH2AX), an early marker of DNA damage46, in cells from the
bone marrow and spleen of Tet2/3 DKO but not WT, Tet2KO or
Tet3KO mice (Fig. 6a,b). When we exposed WT and Tet2/3 DKO
mice to 6Gy of ionizing irradiation at 1 and 3 weeks after pIpC
injection, there was strong gH2AX induction at 3 h after
irradiation, but the DNA double-strand breaks were rapidly
resolved (6–9 h) in WT cells as shown by the disappearance of
Figure 5 | Changes in gene expression and DNA modiﬁcation (5mCþ5hmC) in Tet2/3 DKO cells. (a) Differential gene expression in WTversus Tet2/3
DKO LSK cells. Red dots—differentially expressed genes (P value r0.05, fold change 41.5 or o0.67; thresholds indicated by blue lines). Grey dots—all
other genes. (b) Gene set enrichment analysis (GSEA) of RNA-Seq data. Myeloid gene signatures are signiﬁcantly enriched for genes upregulated in Tet2/3
DKO versus WT LSK cells. (c) Genome browser visualization showing increased and decreased expression of myeloid (Mpo, Csf1r) and lymphoid (Dntt,
Cd72) genes in Tet2/3 DKO versus control LSK cells. (d) Slight but consistent increase in average DNA modiﬁcation at gene regions in Tet2/3 DKO (red
lines) versus WT LSK cells (blue lines), regardless of whether gene expression is upregulated (top) or downregulated (bottom). Similar results were
obtained for all genes (Supplementary Fig. 17c). Shaded areas¼±1 s.d. TSS, transcription start site; TTS, transcription termination site. (e) Changes in
gene expression versus changes in average DNA methylation for all genes differentially expressed in Tet2/3 DKO LSK versus WT LSK cells. Top, gene
bodies; bottom, promoter regions (TSS±2 kb). Each gene body/TSS region is represented by a dot. Most regions show increased methylation, regardless of
whether they are up- or downregulated in DKO LSK cells relative to WT. (f) Active enhancer regions in LT-HSC43 show increased DNA modiﬁcation
(5mCþ 5hmC) in Tet2/3 DKO versus WT LSK cells. Each bin contains all the CpGs falling within theB7,000 active enhancer regions. Colour scale, density
of CpGs with the indicated methylation levels. Enhancer centres in WT LSK cells show an increased fraction of unmethylated CpGs relative to Tet2/3 DKO
LSK cells (green colour at the bottom), whereas enhancer edges in Tet2/3 DKO LSK cells show an increased fraction of methylated CpGs (5mCþ 5hmC)
compared with WT (red colour at the top). For details, see Supplementary Methods. (g) Graphical representation of increased DNA modiﬁcation in Tet2/3
DKO versus WT LSK cells. Data are from central regions of the enhancers (blue and red rectangles in f).
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Figure 6 | Loss of Tet2 and Tet3 results in DNA damage and impaired DNA repair. (a–c) gH2AX levels in whole-cell lysates from bone marrow (top) and
spleen (bottom), assessed by immunoblotting. Actin serves as a loading control. (a) Progressive increase in gH2AX levels in bone marrow and spleen of
Tet2/3 DKO mice with time after pIpC injection. (b) Accumulation of gH2AX in bone marrow and spleen of Tet2/3 DKO but not Tet2KO or Tet3KO mice,
3 weeks after pIpC injection. (c) Impaired DNA repair in Tet2/3 DKO cells. WTand DKO mice were exposed to 6Gy of ionizing radiation 3 weeks after pIpC
injection, single-cell suspensions of bone marrow and spleens were prepared at the indicated times, and DNA repair kinetics were assessed by
immunoblotting. Similar results were obtained 1 week after pIpC injection (Supplementary Fig. 19a). (d–g) DNA damage repair is impaired in Tet2/3 DKO
myeloid-lineage cells. LSK (d), GMP (e) and Mac-1þ cells in bone marrow (f), or Mac-1þ cells in spleen (g) were sorted from WT and DKO mice at 3
weeks after pIpC injection, exposed to 6Gy of ionizing radiation, and DNA repair kinetics were assessed by immunocytochemistry. LSK cells repair DNA
damage efﬁciently, whereas GMP and Mac-1þ cells do not. Similar results were obtained using tamoxifen-injected Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ ERT2-Creþ mice
(Supplementary Fig. 19b–d). Scale bar, 5 mm. (h) Increase in gH2AX levels in Mac-1þ cells sorted from bone marrow of DKO mice 3–4 weeks after pIpC
injection. (i) TET proteins control expression of DNA repair genes in myeloid cells. Quantitative reverse transcription–PCR of Mac-1þ cells sorted from
bone marrow of WT (Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ) and DKO (Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ Mx1-Creþ ) mice 3–4 weeks after pIpC injection. Results are expressed as fold change over
WTcells (set to 1; three independent experiments; means±s.e.m.). Similar results were observed in sorted Mac-1þ cells from WT (Tet2þ /þTet3ﬂ/ﬂ) and
Tet2 / Tet3ﬂ/ﬂ Mx1-Creþ mice (Supplementary Fig. 19e). HR, homologous recombination; NHEJ, non-homologous end-joining; ND, not detected.
*Po0.05, **Po0.005, ***Po0.0005 (Student’s t-test).
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gH2AX. In cells from injected DKO mice, however, gH2AX
persisted at high levels until 9 h after irradiation (Fig. 6c;
Supplementary Fig. 19a), indicating that gH2AX accumulation
in the DKO cells was due to impairment of DNA damage
repair.
Notably, this defect was most prominent in differentiated cell
populations compared with early precursors. LSK, GMP and
Mac-1þ cells were isolated from bone marrow and spleen of WT
and DKO mice that had been injected with pIpC 3 weeks
previously, and exposed to ionizing radiation; the appearance and
resolution of DNA double-strand breaks was then examined by
immunocytochemistry for gH2AX (Fig. 6d–g). Early precursor
(LSK) cells from WT and Tet2/3 DKO bone marrow developed
equivalent levels of gH2AX foci at 1 and 3 hr after irradiation,
and these were efﬁciently resolved with similar kinetics (Fig. 6d);
further along the differentiation pathway, GMP cells from DKO
mice displayed heightened levels of ionizing radiation-induced
gH2AX foci compared with WT GMP cells and were less capable
of removing gH2AX over time (Fig. 6e); and ﬁnally, the most
mature cell population, Mac-1þ myeloid cells sorted from bone
marrow and spleen, displayed high levels of gH2AX foci even
before irradiation (0 h), and were unable to repair gH2AX foci
even 22 h after irradiation (Fig. 6f,g). Similar results were
obtained in Tet2 / Tet3ﬂ/ﬂ ERT2-Creþ mice when Tet3
was deleted by tamoxifen treatment in vivo (Supplementary
Fig. 19b–d).
We showed that TET proteins inﬂuence the expression of DNA
damage repair genes in myeloid cells, and that TET loss-of-
function can in some cases lead to overt genomic instability.
Mac-1þ cells were sorted from WT (Tet2ﬂ/ﬂ Tet3ﬂ/ﬂor
Tet2þ /þTet3ﬂ/ﬂ) and DKO (Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ Mx1-Creþ ) mice
at 3B4 weeks after pIpC injection (Fig. 6h), and quantitative
reverse transcription–PCR was performed to assess the expres-
sion of genes implicated in homologous recombination and non-
homologous end-joining. The expression of 53bp1, Rad51 and
Rpa1 was increased in Tet2/3 DKO cells compared with WT cells,
whereas the expression of Rad54, Xrcc2, Xrcc3, Xrcc5, Xrcc6 and
Prkdc was decreased (Fig. 6i). Similar results were obtained using
Tet2 / Tet3ﬂ/ﬂ Mx1-Creþmice (Supplementary Fig. 19e). We
then submitted bone marrow samples from four sick Tet2/3-
deﬁcient DKO mice for G-banded karyotyping; these samples
contain primarily differentiated Mac-1þ cells. In one of these
samples, 6 of 20 DKO cells examined displayed an unbalanced
translocation of distal chromosome 6 to distal chromosome 3
(Supplementary Fig. 20). Together, these results link TET loss-of-
function to progressive impairment of the DNA damage
response, and show that TET function is important for genome
integrity in certain cell types.
Discussion
In this study, we demonstrate for the ﬁrst time a causal
association of TET loss-of-function with the rapid occurrence
of a malignant cancer. Induced deﬁciency of both Tet2 and
Tet3 in mice leads to the almost complete loss of 5hmC
in the bone marrow and spleen, and concomitantly to the rapid
and cell-autonomous development of an aggressive, fully
penetrant and transmissible myeloid leukaemia. This phenotype
is not observed with mice lacking only Tet2 or Tet3, indi-
cating that Tet2 and Tet3 function redundantly to suppress
oncogenesis.
Typically, cancer initiation, progression and metastasis involve
multiple steps of progressive cellular dysfunction, including loss
of genome integrity and the consequent acquisition of mutations
that promote cell transformation47. These processes are rarely the
result of a single oncogenic hit, but require multiple mutagenic
events that generally accumulate over a long time period. The
striking feature of our study is that acute TET loss-of-function
accelerates oncogenesis, such that uncontrolled cell proliferation
and genome instability develop in a compressed time span of only
B4–5 weeks. Profound loss of function is required, since mice
lacking individual TET proteins may show precancerous
symptoms but develop full-blown malignancy only sporadically
and at a very late age, if at all8,15–18. Thus TET proteins are
required to maintain genome stability, and collectively constitute
a major class of tumour suppressors in cells.
While TET2 mutations are thought to be driver mutations in
haematopoietic malignancies, whole-exome sequencing of large
cancer cohorts has revealed only rare mutations in TET1 or TET3
(refs 19,48,49). However, numerous studies have demonstrated
substantial decreases in 5hmC levels in diverse human cancers,
even in the absence of TET-coding region mutations2. In several
cases, decreased 5hmC levels reﬂect decreased TET messenger
RNA or protein expression secondary to upregulation of E3
ligases or microRNAs50–53, or correlate with increased DNA
methylation at TET gene promoters18,54. In other cases,
inhibition of TET function appears to be the underlying cause:
for instance in many glioblastomas and myeloid leukaemias,
recurrent dominant mutations in IDH1 and IDH2, the cellular
enzymes that produce 2-oxoglutarate, result in massively
increased levels of 2-hydroxyglutarate55, an ‘oncometabolite’
that interferes with the activity of TET enzymes and other
dioxygenases56. On the basis of these ﬁndings, we explored the
relation of profound TET loss-of-function to cell lineage
speciﬁcation and oncogenic transformation. Our data document
a causal relation between TET loss-of-function and cancer, and
argue against the possibility that decreased 5hmC in cancer cells
merely reﬂects their rapid proliferation.
Notably, we observed no consistent relation between DNA
modiﬁcation and gene expression in DKO versus WT LSK cells.
As expected from the fact that TET proteins facilitate DNA
demethylation, early progenitor (LSK) cells from Tet2/3 DKO
mice showed increased DNA modiﬁcation relative to WT LSK
cells, and the biggest differences were observed at genomic
regions where DNA modiﬁcation levels are intermediate: canyon
edges, gene bodies and enhancers. Moreover, transcriptional
proﬁling revealed clear changes in gene expression in DKO versus
WT LSK cells, including decreased expression of stem cell genes,
altered lineage priming and strong myeloid skewing. However,
only a minority of regions with increased DNA methylation
displayed decreased transcription of the associated genes.
Potentially, increased DNA methylation might better correlate
with decreased gene transcription in GMP or Mac-1þ cells that
are further along the myeloid differentiation pathway than the
LSK progenitor cells examined here. If so, it would underscore the
view that altered DNA methylation is a late consequence of
altered gene transcription rather than its direct cause (reviewed
in refs 57,58).
What mechanisms underlie the lineage skewing induced by
deletion of both Tet2 and Tet3, if increased DNA methylation is
not the primary cause? An important factor may be the profound
loss of TET-generated oxi-mC bases in Tet2/3 DKO cells. 5hmC is
present at high levels at active enhancers and the gene bodies of
highly transcribed genes59; moreover, both 5hmC and 5fC are
stable modiﬁcations that are lost through DNA replication in
somatic cells60. Therefore, profound loss of 5hmC in Tet2/3 DKO
cells would be expected to affect gene transcription only after
several replication cycles. If, as recently reported61, 5fC and 5caC
directly affect the processivity of RNA polymerase II, oxi-mC
would be most heavily diluted, and gene transcription would be
most prominently decreased, at genes expressed in actively
proliferating cells that encode key signalling proteins and
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transcriptional regulators that shape cell lineage commitment and
function62.
The hypothesis that oxi-mC may be more relevant than 5mC is
also supported by recent ﬁndings that mice lacking either
Dnmt3a or Tet2 in HSC show similar phenotypes in terms of
augmented HSC repopulation capacity, myeloid skewing
and ultimately myeloid transformation8,15–17,63–65. DNMT3A
produces 5mC, the substrate for TET proteins66. Therefore,
impaired function of these two enzymes would be expected to
have opposite effects on DNA methylation, resulting in overall
decreases and increases in 5mC, respectively, but would be similar
in terms of decreasing oxi-mC (Dnmt3a-deﬁcient cells have lower
levels of the TET substrate 5mC and therefore less oxi-mC,
whereas TET2 mutations are loss-of-function mutations and
therefore also have low oxi-mC2). Thus the similar biological
phenotypes of Tet2- and Dnmt3a-deﬁcient mice could plausibly
reﬂect loss of oxi-mC in each case.
In addition to skewing to the myeloid lineage, Tet2/3 DKO cells
display uncontrolled proliferation and rapid progression to
oncogenic transformation, a process accompanied by increased
levels of the DNA damage marker phospho-H2AX and slower
resolution of this mark. These features were most apparent in
cells that had progressed along the differentiation pathway rather
than in early precursors. Mac-1þ cells sorted from bone marrow
and spleen of Tet2/3 DKO mice showed altered expression of
many genes encoding proteins in the homologous recombination
and non-homologous end-joining pathways of DNA repair, but it
is not clear whether this is a cause or a consequence of the
observed defects in DNA damage responses. Further mechanistic
studies are necessary to determine how TET loss-of-function
leads to impaired DNA damage.
Methods
Acute deletion of Tet2 and Tet3. Tet2 / , Tet2ﬂ/ﬂ and Tet3ﬂ/ﬂ mice have been
described previously12,17. To induce conditional excision of ﬂoxed alleles using the
Mx1-Cre recombinase, pIpC (polyinosinic–polycytidylic acid, Sigma: 300 mg per
mouse) in PBS was injected ﬁve times intraperitoneally every other day for a
total of ﬁve injections. To delete ﬂoxed alleles using the ERT2-Cre recombinase,
tamoxifen (Sigma) was solubilized at 10mgml 1 in corn oil (Sigma) and delivered
into mice by intraperitoneal injection of 2mg tamoxifen per mouse every day for
5 consecutive days. The day of the last pIpC or tamoxifen injection was designated
Day 0 (Fig. 1b). In Fig. 1b, WT indicates Mx1-Creþ ; Tet2þ /þ Tet3ﬂ/ﬂ Mx1-Cre
or Tet2þ /þ Tet3ﬂ/þ Mx1-Cre genotypes; DKO indicates Tet2 / Tet3ﬂ/ﬂ Mx1-
Creþ genotype; Tet2-deﬁcient (T2KO) indicates Tet2 / Tet3ﬂ/ﬂ Mx1-Cre or
Tet2 / Mx1-Creþ genotypes; and Tet3-deﬁcient (Tet3KO) indicates the Tet3ﬂ/ﬂ
Mx1-Creþ genotype. In Fig. 3c, WT indicates Tet3ﬂ/ﬂ, Tet2ﬂ/ﬂ Tet3ﬂ/þ or Tet2ﬂ/ﬂ
Tet3ﬂ/ﬂ; T2KO indicates Tet2 / or Tet2 / Tet3ﬂ/ﬂ; T3KO indicates Tet3ﬂ/ﬂ
Mx1-Creþ ; and DKO indicates Tet2 / Tet3ﬂ/ﬂ Mx1-Creþ mice. For all other
experiments, Tet2þ /þ Tet3ﬂ/ﬂ Mx1-Cre or Tet2þ /þ Tet3ﬂ/þ Mx1-Cre mice
were used as WT controls. Efﬁcient gene deletion in sorted HSPCs was veriﬁed by
real-time reverse transcription–PCR. The pIpC-injected mice were assessed on a
daily basis for survival and development of any haematopoietic abnormalities. For
all experiments described here, mice were killed immediately if they were hunched
or slow-moving, had piloerection of the fur, if their eyes were sunken or closed or
they were not responsive to handling. To draw a Kaplan–Meier survival plot, it was
assumed that the mice would live 1 more day unless killed, so death was not
required as an end point. All cell or mouse irradiation procedures were performed
using RS2000 Biological Irradiator (Rad Source Technologies, Inc.). All animal
procedures were approved by the La Jolla Institute Institutional Animal Care and
Use Committee and were conducted in accordance with institutional guidelines.
In vivo transplantation experiments. For competitive engraftment assays, total
bone marrow cells were isolated from tibiae and femurs of Tet2þ /þ Tet3ﬂ/ﬂ
Mx1-Cre or Tet2 / Tet3ﬂ/ﬂ Mx1-Creþ testor mice (CD45.2þ background),
and red blood cells were lysed by incubation with ACK lysis buffer (0.15 M NH4Cl,
10mM KHCO3 and 0.1mM EDTA) at room temperature for 1min. Cells were
counted using BD Accuri C6 Flow Cytometer (BD Biosciences). One million
tester-derived cells were mixed with equal number of competitor bone marrow
cells (CD45.1þ background) and the mixtures were injected into lethally
irradiated (10Gy, two split doses with a 3-h interval) congenic (CD45.1þ )
B6.SJL-PtprcaPepcb/BoyJ mice (Jackson Laboratories). At 4 weeks post transplant,
chimeric mice were administered intraperitoneally with 300 mg of poly(I:C) per
mouse in PBS every other day for a total of ﬁve injections (week 0) to excise ﬂoxed
alleles. To evaluate the percentage of tester-derived cells and different lineage
contribution, peripheral blood was collected from the chimeric mice via
retro-orbital sinus under anaesthesia at 4, 8 and 10 weeks after injection, depleted
of red blood cells and stained with combinations of antibodies against CD45.1,
CD45.2, CD3e, CD19 and Mac-1, and the percentage of haematopoietic subsets
within the CD45.2þ population was analysed by ﬂow cytometry. Kaplan–Meier
plots were drawn based on the monitoring criteria described above. To evaluate the
transplantability of disease, splenocytes were isolated from Tet2þ /þ Tet3ﬂ/ﬂ
Mx1-Cre and Tet2 / Tet3ﬂ/ﬂ Mx1-Creþ (for Fig. 4d–k) or Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ
Mx1-Cre and Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ Mx1-Creþ (for Supplementary Fig. 13) mice at
about 3.5 or 4.5 weeks following pIpC injection, respectively, depleted of red blood
cells and 2 106 cells in PBS were injected intravenously via retro-orbital route
into sublethally irradiated (600 cGy) C57BL/6 recipient mice. For transfer of bone
marrow cells in Supplementary Fig. 14, bone marrow cells were isolated from
Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ ERT2-Cre and Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ ERT2-Creþ at 3 weeks following
tamoxifen injection, depleted of red blood cells and 2 106 cells in PBS were
injected intravenously via retro-orbital route into sublethally irradiated (600 cGy)
C57BL/6 recipient mice. For transfer of Mac-1þ cells in Supplementary Fig. 15,
2 106 Mac-1þ cells sorted from Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ Mx1-Cre and Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ
Mx1-Creþ at about 4.5 weeks following pIpC injection were combined with equal
number of WT bone marrow helper cells, followed by injection into lethally
irradiated (10Gy, two split doses with a 3-h interval) C57BL/6 recipient mice.
Then, the recipient mice were monitored for survival every day. Mice were killed
when they met our monitoring criteria described above and histological or
cytological analyses were carried out as described.
Colony-forming assay in vitro. For colony-forming assay using splenocytes and
liver cells (Fig. 1g), cells were harvested from spleens and livers of Tet2þ /þ Tet3ﬂ/ﬂ
Mx1-Cre and Tet2 / Tet3ﬂ/ﬂ Mx1-Creþ mice about 3 weeks following pIpC
injections, depleted of red blood cells and plated at 105 cells per 35-mm dish in
duplicate into cytokine-supplemented methylcellulose medium (Methocult M3534,
STEMCELL Technologies). Colony-forming units were photographed and counted
on day 7.
For colony-forming assay using sorted LSK or GMP cells (Fig. 3c), LSK or GMP
cells were sorted from the bone marrow of WT (Tet2ﬂ/ﬂ, Tet2ﬂ/ﬂ Tet3ﬂ/ﬂ or Tet3ﬂ/þ
Tet3ﬂ/ﬂ), Tet2KO (Tet2 / or Tet2 / Tet3ﬂ/ﬂ), Tet3KO (Tet3ﬂ/ﬂ Mx1-Creþ )
or DKO (Tet2 / Tet3ﬂ/ﬂ Mx1-Creþ ) mice at 4 weeks after pIpC injection
and seeded at a density of 1,000 cells per 35-mm dish in duplicate into cyto-
kine-supplemented methylcellulose media (Methocult M3534, STEMCELL
Technologies). For experiments in Supplementary Fig. 9c–f, LSK cells were sorted
from the bone marrow of Tet2þ /þ Tet3ﬂ/ﬂ ERT2-Cre and Tet2 / Tet3ﬂ/ﬂ
ERT2-Creþ mice and seeded at a density of 1,000 cells per 35-mm dish in duplicate
into cytokine-supplemented methylcellulose media (Methocult M3534). To induce
Tet3 deletion in vitro, 4-hydroxytamoxifen (Sigma) was dissolved in ethanol at
4mgml 1 and diluted immediately before treatment for a ﬁnal concentration of
1 mM. Colonies propagated in culture were scored after 7–9 days. For serial
replating experiments, colonies in the dish were pooled and cells were resuspended
and counted, and re-seeded at a density of 1,000 cells per dish in duplicate for a
total of four platings.
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